[go: up one dir, main page]

CN1249750A - (e)-4,6-二氯-3-(2-氧代-1-苯基吡咯烷-3-亚基甲基)-1h-吲哚-2-甲酸的结晶水合钠盐) - Google Patents

(e)-4,6-二氯-3-(2-氧代-1-苯基吡咯烷-3-亚基甲基)-1h-吲哚-2-甲酸的结晶水合钠盐) Download PDF

Info

Publication number
CN1249750A
CN1249750A CN98803053A CN98803053A CN1249750A CN 1249750 A CN1249750 A CN 1249750A CN 98803053 A CN98803053 A CN 98803053A CN 98803053 A CN98803053 A CN 98803053A CN 1249750 A CN1249750 A CN 1249750A
Authority
CN
China
Prior art keywords
sodium salt
crystalline hydrate
hydrate form
compound
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98803053A
Other languages
English (en)
Chinese (zh)
Inventor
Z·奇马洛斯蒂
P·马拉格尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Glaxo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo SpA filed Critical Glaxo SpA
Publication of CN1249750A publication Critical patent/CN1249750A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
CN98803053A 1997-03-05 1998-03-03 (e)-4,6-二氯-3-(2-氧代-1-苯基吡咯烷-3-亚基甲基)-1h-吲哚-2-甲酸的结晶水合钠盐) Pending CN1249750A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound
GB9704498.6 1997-03-05

Publications (1)

Publication Number Publication Date
CN1249750A true CN1249750A (zh) 2000-04-05

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98803053A Pending CN1249750A (zh) 1997-03-05 1998-03-03 (e)-4,6-二氯-3-(2-氧代-1-苯基吡咯烷-3-亚基甲基)-1h-吲哚-2-甲酸的结晶水合钠盐)

Country Status (29)

Country Link
EP (1) EP0966463A1 (is)
JP (1) JP2001513796A (is)
KR (1) KR20000075907A (is)
CN (1) CN1249750A (is)
AP (1) AP9901637A0 (is)
AR (1) AR011178A1 (is)
AU (1) AU6825198A (is)
BG (1) BG103779A (is)
BR (1) BR9808305A (is)
CA (1) CA2282851A1 (is)
CO (1) CO4940415A1 (is)
EA (1) EA199900710A1 (is)
EE (1) EE9900387A (is)
GB (1) GB9704498D0 (is)
HR (1) HRP980114A2 (is)
HU (1) HUP0002109A2 (is)
ID (1) ID24207A (is)
IL (1) IL131489A0 (is)
IS (1) IS5166A (is)
NO (1) NO994303L (is)
NZ (1) NZ337315A (is)
OA (1) OA11154A (is)
PE (1) PE51399A1 (is)
PL (1) PL335652A1 (is)
SK (1) SK119699A3 (is)
TR (1) TR199902117T2 (is)
WO (1) WO1998039327A1 (is)
YU (1) YU43499A (is)
ZA (1) ZA981791B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
AU6825198A (en) 1998-09-22
ID24207A (id) 2000-07-13
BG103779A (en) 2000-06-30
AR011178A1 (es) 2000-08-02
SK119699A3 (en) 2000-05-16
TR199902117T2 (xx) 2000-03-21
KR20000075907A (ko) 2000-12-26
JP2001513796A (ja) 2001-09-04
PE51399A1 (es) 1999-06-07
IL131489A0 (en) 2001-01-28
CO4940415A1 (es) 2000-07-24
CA2282851A1 (en) 1998-09-11
AP9901637A0 (en) 1999-09-30
EA199900710A1 (ru) 2000-04-24
EE9900387A (et) 2000-04-17
NZ337315A (en) 2001-02-23
HUP0002109A2 (hu) 2001-04-28
BR9808305A (pt) 2000-05-16
GB9704498D0 (en) 1997-04-23
EP0966463A1 (en) 1999-12-29
HRP980114A2 (en) 1998-12-31
IS5166A (is) 1999-08-27
PL335652A1 (en) 2000-05-08
YU43499A (sh) 2000-12-28
OA11154A (en) 2003-04-16
WO1998039327A1 (en) 1998-09-11
NO994303L (no) 1999-11-03
ZA981791B (en) 1999-09-03
NO994303D0 (no) 1999-09-03

Similar Documents

Publication Publication Date Title
AP480A (en) 3-Substituted indole 2-carboxylic acid derivatives.
JPH10511973A (ja) タキキニンアンタゴニスト活性を有するピペリジン誘導体
JP2001513557A (ja) 痛みを処置するための方法
WO2003080633A1 (fr) Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame
CN1312135C (zh) 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
JPH0681723B2 (ja) 非−白金抗癌薬によりひき起こされる嘔吐の軽減用治療剤
CN1249750A (zh) (e)-4,6-二氯-3-(2-氧代-1-苯基吡咯烷-3-亚基甲基)-1h-吲哚-2-甲酸的结晶水合钠盐)
KR100488284B1 (ko) 시스-치환된 아미노사이클로프로판 유도체 및 이를 함유하는 항균약
JP2000516257A (ja) タキキニンアンタゴニスト
JP2001513532A (ja) 痛みを処置するための方法
JP2001518901A (ja) キノリン−2−カルボン酸誘導体およびその興奮性アミノ酸拮抗薬としての使用
JP4311901B2 (ja) 複素環誘導体
CN101516842A (zh) 阿托伐他汀镁晶型b4及其方法
KR100274736B1 (ko) 6-엔-(엘-에이엘에이-엘-에이엘에이)-트로바플록사신 전구약물의 폴리모프
CN100387580C (zh) 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
CZ314799A3 (cs) Krystalická hydratovaná sodná sůl kyseliny (E)-4,6-dichlor-3-(2-oxo-l-fenylpyrrolidin-3- ylidenmethyl)-lH-indol-2-karboxylové
MXPA00009646A (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity
HK1016192A (en) Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication